Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers

Figure 4

Core tumor-associated embryonic mammary genes associate significantly with key clinical parameters in breast cancers. (A) Expression levels of core network activated across independent tumor datasets in ER+ versus ER- breast cancers. Red indicates expression levels upregulated in ER- versus ER+ tumors; green indicates expression levels up in ER+ versus ER- tumors. (B) Five genes (ASPM, BCL11A, SOX11, TPX2, and UCHL1) from the core network in Figure 5A show at least a twofold increase in expression levels in ER- versus ER+ breast cancers in seven datasets [16, 38–43]. (C) Five genes (ASPM, BCL11A, SOX11, TPX2, and UCHL1) from the core network shown in Figure 5A show at least a twofold increase in expression levels in PR- versus PR+ breast cancers in eight datasets [16, 39, 41–46]. (D) Expression levels of core network activated across six independent tumor datasets [16, 40, 42, 47–49] in HER2- versus HER+ breast cancers. Red, expression levels upregulated in HER2- versus HER2+ tumors; green, expression levels upregulated in HER2+ versus HER2- tumors. (E) Significance analysis of microarray (SAM) analysis of ASPM, BCL11A, SOX11, UCHL1, and TPX2 expression according to tumor subtype, as defined by PAM50 [17], in breast cancers in the Lu dataset [40]. (F) SAM analysis of ASPM, SOX11, and TPX2 expression according to grade in breast cancers in Miller dataset [41]. (G) Kaplan-Meier analysis shows significantly reduced overall survival in the high SOX11 as compared with the low-SOX11 subgroup in the van de Vijver dataset [15] (χ2 P value = 0.004; log-rank P value = 0.002133).

Back to article page